BackFaeth Therapeutics Overview
Faeth Therapeutics, Inc.

Faeth Therapeutics Target Price

Where could FTH trade next? Consensus target price: $60.

Get informed when a big investor buys or sells

+ Follow

Share Price

$18.75

Average Target Price

$60.20221.1% upside

5 analysts in the last 4 months

High: $70 | Low: $56

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-15GuggenheimBrad Canino$70273.3% upsideOpen
2026-09-14UBS$59214.7% upsideOpen
2026-08-21NeedhamGil Blum$56198.7% upsideOpen
2026-07-31Raymond JamesSean McCutcheon$56198.7% upsideOpen
2026-07-27Oppenheimer$60220% upsideOpen
2026-06-25Robert W. BairdJack Allen$57204% upsideOpen
2026-06-22H.C. Wainwright$60220% upsideOpen
2026-05-28Loop Capital MarketsChristopher Liu$50166.7% upsideOpen
2024-05-13StephensSudan Loganathan$573.3% downsideOpen
2022-12-13Citigroup$668% downsideOpen

Faeth Therapeutics (FTH) FAQ

Faeth Therapeutics's target price stands at $60. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $60 for FTH implies 221.1% upside versus today's price ($18.75). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Faeth Therapeutics's target price evolved across reporting periods, while the comparison chart places FTH next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Faeth Therapeutics's reading of $60 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.